Poster Presentation 2025 Joint Meeting of the COSA ASM and IPOS Congress

Treatment sequencing of tepotinib in patients with MET exon 14 (METex14) skipping non-small lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study (125779)

Stephanie Gasking 1 , Santiago Viteri 2 , Enriqueta Felip 3 , Egbert F. Smit 4 , Remi Veillon 5 , Xiuning Le 6 , Jo Raskin 7 , Michael Thomas 8 , Myung-Ju Ahn 9 , Frank Griesinger 10 , Marina Chiara Garassino 11 , Hiroshi Sakai 12 , Marie-Noelle Solbes 13 , Erica Velthuis 14 , Andreas Johne 13 , Rolf Bruns 15 , Simone Lang 13 , Niki Karachaliou 13 , Bruce Gaumond 16 , Paul K. Paik 17
  1. Merck Healthcare Pty. Ltd., Macquarie Park, Australia, an affiliate of Merck KGaA
  2. Instituto Oncológico Dr Rosell, Hospital Universitario Dexeus, Grupo Quiron Salud, Barcelona, Spain
  3. Department of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  4. Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands
  5. CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France
  6. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  7. Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium
  8. Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
  9. Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea
  10. Pius-Hospital, University Medicine Oldenburg, Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Oldenburg, Germany
  11. Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, IL, USA
  12. Department of Thoracic Oncology, Ageo Central General Hospital, Saitama, Japan
  13. Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany
  14. Global Program Safety Lead, Merck B.V., Schiphol-Rijk, Netherlands, an affiliate of Merck KGaA
  15. Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany
  16. Global Development Operations, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
  17. Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Background: Tepotinib, an oral MET TKI, is approved in the European Union for advanced/metastatic METex14 skipping NSCLC after immunotherapy (IO) and/or platinum-based chemotherapy (CT), and regardless of prior treatments in other countries including the UK and Switzerland. The VISION study showed robust and durable efficacy and safety of tepotinib in patients with ≥3 years follow-up. We report long-term efficacy data prior/peri/post-tepotinib, treatment interruption details, and data on long-term responders in VISION (data cut-off: May 20, 2024).

Methods: Patients received tepotinib 500 mg (450 mg active moiety) QD. Primary endpoint was objective response (RECIST v1.1) by IRC. Prior/post-tepotinib treatment was investigator’s choice; outcomes were reported per investigator.

Results: Of 313 patients (median age 72.0 years), 164 received tepotinib in 1L with ORR of 57.9%, mDOR of 31.7 months, and mPFS of 12.6 months while 149 received it in 2L+ with ORR of 45.0%, mDOR of 12.6 months, and mPFS of 11.0 months. For patients receiving tepotinib in 2L+ in VISION, 104 patients had previously received platinum-based CT alone, 59 IO monotherapy, and 22 IO-CT. Across all prior treatment lines, ORR was 28.9%, mDOR was 6.0 months, and mPFS was 5.0 months; outcomes with tepotinib in 2L+ were improved.
The median time on treatment was 7.5 months; 19 (6.1%) patients received tepotinib for ≥48 months (maximum 83 months).
Overall, 295 (94.2%) patients discontinued tepotinib. TRAEs led to dose reductions in 104 (33.2%) patients, treatment interruptions in 137 (43.8%) patients, permanent discontinuation in 49 (15.7%) patients, and death in 3 (1.0%) patients. Of patients who discontinued tepotinib, 145 started subsequent treatments; 65 received MET inhibitors.

Conclusions: In VISION, outcomes with tepotinib across treatment lines in patients with ≥3 years follow-up demonstrated robust and durable efficacy (consistent with previously reported findings), particularly in the 1L-setting, supporting its early use in the treatment sequence.